CompletedNot Applicable

Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

United States241 participantsStarted 2008-07

Plain-language summary

This research trial studies prognostic and predictive markers in patients with early stage non-small cell lung cancer receiving chemotherapy. Prognostic markers are patient or tumor factors that predict patient survival independent of treatment. Predictive markers are factors that may influence and predict the outcome of treatment in terms of either response or survival benefit. Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Registration to CALGB9633 for this study * Institutional Review Board (IRB) review and approval at the institution where the laboratory work will be performed is required * Informed consent: * The subject population to be studied in this protocol includes patients selected from CALGB 9633 for whom an available specimen is present at the Alliance Ohio State University (OSU); all such patients have signed a written informed consent document meeting all federal, state, and institutional guidelines as part of entry into that trial * Only cases with adequate tumor formalin FFPE material without depleting the available clinical block(s) are eligible

What they're measuring

Overall survival

Timeframe: up to 3 years

Trial details

NCT IDNCT01294280

SponsorAlliance for Clinical Trials in Oncology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-02-02

View on ClinicalTrials.gov More Lung Cancer trials